Search Within

Ariela Noy

Formats
  1. Meeting Abstract (204)
  2. Journal Article (143)
  3. Research Letter (10)
  4. Book Section (6)
  5. Review (6)
  6. Editorial (2)
  7. Correspondence (1)
  8. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (373)
  2. Department of Medicine (373)
  3. Hematologic Malignancies, Division of (373)
  4. Lymphoma (373)
  5. Survivorship Research (163)
  6. Population Sciences Research Program (150)

More Groups

People
  1. Andrew Zelenetz (187)
  2. Paul Hamlin (144)
  3. David Straus (139)
  4. Steven Horwitz (138)
  5. Maria Palomba (131)
  6. Alison Moskowitz (118)

More People

Years
  1. 2025 (9)
  2. 2024 (27)
  3. 2023 (24)
  4. 2022 (15)
  5. 2021 (30)
  6. 2020 (26)

More Years

Publications
  1. Blood (166)
  2. Journal of Clinical Oncology (42)
  3. Hematological Oncology (19)
  4. Leukemia and Lymphoma (15)
  5. Blood Advances (13)
  6. Annals of Oncology (12)

More Publications

Publishers
  1. American Society of Hematology (179)
  2. American Society of Clinical Oncology (43)
  3. Wiley Blackwell (23)
  4. Elsevier Inc. (21)
  5. Taylor & Francis Group (15)
  6. Ferrata Storti Foundation (12)

More Publishers

Results (373)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
    Research Letter

    Stuver, R.; Shah, G. L.; Korde, N. S.; Roeker, L. E.; Mato, A. R.; Batlevi, C. L.; Chung, D. J.; Doddi, S.; Falchi, L.; Gyurkocza, B.; more...
    Cancer Cell (2022)

    Fulltext@MSK | Save
  • Predictors of adequacy and adverse events during spleen biopsy in oncologic patients
    Meeting Abstract

    Kunin, H.; Wijetunga, N.; Erinjeri, J.; Noy, A.; Deipolyi, A.
    Journal of Vascular and Interventional Radiology (2022)

    Fulltext@MSK | Save
  • Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
    Journal Article

    Lin, R. J.; Owens, C. N.; Drill, E.; Iannotta, A.; Oliveros, M.; Schick, D. L.; Noy, A.; Gerecitano, J. F.; Drullinsky, P. R.; Caron, P. C.; more...
    Haematologica (2022)

    Fulltext@MSK | Save
  • Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: A single-center experience
    Journal Article

    Pak, T. K.; Dixon, B. N.; Buege, M. J.; Dao, P. H.; Leary, M. H.; Jarrett, J. C.; Duggan, T. A.; Caron, P.; Falchi, L.; Hamlin, P.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schöder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Novel genetic subgroups inform on shared pathobiology within adult and pediatric Burkitt lymphoma
    Meeting Abstract

    Thomas, N.; Dreval, K.; Gerhard, D. S.; Hilton, L. K.; Abramson, J. S.; Bartlett, N. L.; Bethony, J.; Bowen, J.; Bryan, A.; Casper, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save